Samit Hirawat, MD

Dr. Hirawat brings nearly three decades of biopharmaceutical industry experience to the Pacira Board of Directors. He most recently served as the Chief Medical Officer and Head of Global Drug Development at Bristol Myers Squibb (NYSE: BMY), a multinational pharmaceutical company, where he oversaw early- and late-stage product development across all therapeutic areas, from proof-of-concept to commercialization. Dr. Hirawat’s extensive experience in a range of roles in drug development includes world-class clinical trial design, oversight of operational execution, regulatory submissions and approvals worldwide. Over the more than 6 years at Bristol Myers Squibb, he oversaw approval of 13 New Molecular Entities across modalities and provided leadership contributions to five major acquisitions and multiple collaborations and partnerships for the company.

Prior to his time at BMS, Dr. Hirawat held senior executive roles and led clinical development programs in multiple indications at Novartis (NYSE: NVS), where he was Executive Vice President and Head of Oncology Development, as well as at PTC Therapeutics (Nasdaq: PTCT) and Pfizer (NYSE: PFE).

Dr. Hirawat earned his Bachelor of Medicine, Bachelor of Surgery (MBBS) at Sawai Man Singh Medical College in India and completed his internal medicine residency and medical oncology training at North Shore University Hospital in New York. Dr. Hirawat is a member of the board of trustees of Penn Medicine at the University of Pennsylvania and serves as an independent director on the board of K-2 Therapeutics, LLC, a privately-held biotechnology research company.